Perjeta
Perjeta ingredients
| Active ingredient | Strength |
|---|---|
| Pertuzumab | 30 mg/mL |
What Perjeta is used for
The FDA lists the approved uses on the official label (below). In the EU, pertuzumab is approved as Perjeta for:
Metastatic Breast Cancer: Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Neoadjuvant Treatment of Breast Cancer: Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Perjeta
- Generic name
- Pertuzumab
- Made by
- Genentech, Inc.
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- Drug class
- HER2/neu Receptor Antagonist
- FDA approval
- Biologic licence (BLA) BLA125409
- On the US market since
- 2012
Official information
- Perjeta prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Pertuzumab)
In India
- Pertuzumab: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Perjeta?
Perjeta (Pertuzumab) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Perjeta?
Perjeta contains Pertuzumab (30 mg/mL).
Is Perjeta approved in Europe?
The same active substance is approved in the EU as Perjeta, Phesgo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA